For the TBG-siCK2 drug, the dose levels 1.0 and 0.01 mg/kg resulted in significantly slowed tumor growth relative to the control group treated with TBG-siCON1 (p = 0.031 and p = 0.007, respectively; Figure 2A). The gene discussed is SERPINA7; the disease is neoplasm.